89bio, Inc. (ETNB) NASDAQ

14.70

+0.005(+0.03%)

Updated at September 29 04:00PM

Currency In USD

89bio, Inc.

Address

142 Sansome Street

San Francisco, CA 94104

United States of America

Phone

415 432 9270

Sector

Healthcare

Industry

Biotechnology

Employees

93

First IPO Date

November 11, 2019

Key Executives

NameTitlePayYear Born
Mr. Rohan PalekarChief Executive Officer & Director999,8341966
Mr. Francis W. SarenaChief Operating Officer590,4731971
Mr. Ryan Stephen MartinsChief Financial Officer646,5251978
Mr. Quoc Le-NguyenChief Technical Officer693,0991968
Dr. Harry Mansbach M.D.Chief Medical Officer717,3831965
Mr. Shiva K. Natarajan CPASenior Vice President of Finance & Principal Accounting Officer01966
Ms. Melissa AbelSenior Vice President of Commercial Strategy0N/A
Mr. Michael BaldwinSenior Vice President & Head of Quality0N/A
Ms. Annie J. Chang M.B.A.Vice President of Investor Relations & Corporate Communications0N/A
Ms. Amanda KuriharaVice President of People & Culture0N/A

Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.